JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

Anticoagulation in patients with acute ischemic stroke and atrial fibrillation--a balance of risks and benefits.

OBJECTIVES: We reviewed the current literature regarding anticoagulation in patients presenting with acute ischemic stroke and atrial fibrillation.

METHODS: A systematic literature search was performed using PUBMED. All relevant articles including meta-analysis, original case studies and cross-references from relevant articles were included in this review.

RESULTS: Atrial fibrillation is a thrombogenic state and predisposes to acute embolic strokes. Most studies do not show any mortality or morbidity benefit of anticoagulation with unfractionated or low-molecular weight heparins in patients with acute stroke. The relative risk of hemorrhagic transformation of the ischemic stroke is higher than the lowering of stroke due to recurrent embolism. Large infarcts, greater patient age, extensive small vessel disease and uncontrolled hypertension should prompt a further delay in anti-coagulation.

CONCLUSION: Avoid anticoagulation with heparins in patients with acute ischemic stroke with atrial fibrillation for 7-10 days. Further studies are needed to delineate when to start oral anticoagulation.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app